Literature DB >> 8631356

Alternative splicing of the pyruvate kinase M gene in a minigene system.

M Takenaka1, K Yamada, T Lu, R Kang, T Tanaka, T Noguchi.   

Abstract

The M1-type and M2-type isozymes of pyruvate kinase are produced from a single gene by mutually exclusive use of exons 9 and 10. Selection of exon 10 generates the M2 type, which occurs in most tissues, whereas the M1 type is expressed by use of exon 9 only in skeletal muscle, heart and brain. We investigated the mechanism by which exon 10, but not exon 9 is selected in M2-expressing cells by transfecting minigenes containing exon 9 and/or exon 10 in cells and by analyzing the transcripts using reverse-transcriptase polymerase chain reaction. Deletion of the most conserved region in intron 8 did not affect selection of exon 10 in dRLh-84 cells, which express only the M2 type. Exclusion of exon 10 from the minigene resulted in two major spliced products. One included correctly spliced exon 9 and the other skipped this exon. Similar splicing patterns were observed when these minigenes were transfected in hepatocytes which express the L type, but not M1 or M2 types. The 5' splice site but not the 3' splice site of exon 9 was found to be hardly recognized by the splicing machinery in dRLh-84 cells. Mutation of the 5' splice site sequence of exon 9 to that of exon 10 and vice versa did not change the splicing patterns. However, mutation of this site of exon 9 to a perfectly complementary sequence of U1 snRNA resulted in selection of exon 9 correctly spliced to exon 10. A 9-10 fusion exon (constructed by substitution of 68 bases of the 3' portion of exon 9 and 33 bases of the 5' portion of intron 9 for the corresponding regions of exon 10 and intron 10) was also correctly incorporated into a major product together with exon 10. Thus, we propose that exon 9 is not recognized in non M1-expressing cells due to the weak signal of its 5' splice site and that, although the 5' splicing signal of exon 10 also appears to be weak, this exon can be recognized in these cells because the 5' recognition signal may be relatively strengthened by cis-acting element(s) which may be present in the 3' portion of exon 9 and the 5' portion of intron 9 and/or the corresponding regions of exon 10 and intron 10.

Mesh:

Substances:

Year:  1996        PMID: 8631356     DOI: 10.1111/j.1432-1033.1996.00366.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  16 in total

1.  Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.

Authors:  Jian-kang Jiang; Matthew B Boxer; Matthew G Vander Heiden; Min Shen; Amanda P Skoumbourdis; Noel Southall; Henrike Veith; William Leister; Christopher P Austin; Hee Won Park; James Inglese; Lewis C Cantley; Douglas S Auld; Craig J Thomas
Journal:  Bioorg Med Chem Lett       Date:  2010-04-11       Impact factor: 2.823

2.  2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.

Authors:  Martin J Walsh; Kyle R Brimacombe; Henrike Veith; James M Bougie; Thomas Daniel; William Leister; Lewis C Cantley; William J Israelsen; Matthew G Vander Heiden; Min Shen; Douglas S Auld; Craig J Thomas; Matthew B Boxer
Journal:  Bioorg Med Chem Lett       Date:  2011-09-14       Impact factor: 2.823

Review 3.  The role of RNA alternative splicing in regulating cancer metabolism.

Authors:  Itamar Kozlovski; Zahava Siegfried; Adi Amar-Schwartz; Rotem Karni
Journal:  Hum Genet       Date:  2017-04-20       Impact factor: 4.132

Review 4.  PKM2, cancer metabolism, and the road ahead.

Authors:  Talya L Dayton; Tyler Jacks; Matthew G Vander Heiden
Journal:  EMBO Rep       Date:  2016-11-17       Impact factor: 8.807

5.  Exon-centric regulation of pyruvate kinase M alternative splicing via mutually exclusive exons.

Authors:  Zhenxun Wang; Deblina Chatterjee; Hyun Yong Jeon; Martin Akerman; Matthew G Vander Heiden; Lewis C Cantley; Adrian R Krainer
Journal:  J Mol Cell Biol       Date:  2011-11-01       Impact factor: 6.216

6.  Oncogenic Kinase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-like Cells.

Authors:  Zhifen Zhou; Min Li; Lin Zhang; Hong Zhao; Özgür Şahin; Jing Chen; Jean J Zhao; Zhou Songyang; Dihua Yu
Journal:  Cancer Res       Date:  2018-02-12       Impact factor: 12.701

7.  HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer.

Authors:  Charles J David; Mo Chen; Marcela Assanah; Peter Canoll; James L Manley
Journal:  Nature       Date:  2009-12-13       Impact factor: 49.962

8.  Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.

Authors:  Matthew B Boxer; Jian-kang Jiang; Matthew G Vander Heiden; Min Shen; Amanda P Skoumbourdis; Noel Southall; Henrike Veith; William Leister; Christopher P Austin; Hee Won Park; James Inglese; Lewis C Cantley; Douglas S Auld; Craig J Thomas
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

Review 9.  Nutrient and hormonal regulation of pyruvate kinase gene expression.

Authors:  K Yamada; T Noguchi
Journal:  Biochem J       Date:  1999-01-01       Impact factor: 3.857

10.  ERK2-Pyruvate Kinase Axis Permits Phorbol 12-Myristate 13-Acetate-induced Megakaryocyte Differentiation in K562 Cells.

Authors:  Noor Chaman; Mohammad Askandar Iqbal; Farid Ahmad Siddiqui; Prakasam Gopinath; Rameshwar N K Bamezai
Journal:  J Biol Chem       Date:  2015-08-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.